Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

GND
128928654
ORCID
0000-0002-9941-5323
Affiliation
Department of General, Visceral and Vascular Surgery, University Hospital Jena, Jena, Germany
Bauschke, Astrid;
GND
1263033237
Affiliation
Department of General, Visceral and Vascular Surgery, University Hospital Jena, Jena, Germany
Altendorf-Hofmann, Annelore;
Affiliation
Department of General, Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany
Homman, Merten;
Affiliation
Department of General, Visceral Surgery, SRH Wald-Klinikum Gera GmbH, Gera, Germany
Manger, Thomas;
Affiliation
Department of General, Visceral and Vascular Surgery, Katholisches Krankenhaus Erfurt, Erfurt, Germany
Pertschy, Jörg;
Affiliation
Thüringen-Kliniken “Georgius Agricola, Saalfeld, Germany
Helfritzsch, Herry;
Affiliation
Clinical Cancer Registry Thuringia with Tumor Center e.V. Erfurt HELIOS Klinikum Erfurt GmbH, Erfurt, Germany
Göbel, Hubert;
GND
172370469
Affiliation
Department of General, Visceral and Vascular Surgery, University Hospital Jena, Jena, Germany
Settmacher, Utz

Abstract Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © The Author(s) 2021

Use and reproduction: